Clinical Trial Update: Tocotrienol Against the Progression of End Stage Liver Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating tocotrienol to slow progression of end-stage liver disease, including nonalcoholic steatohepatitis and non-alcoholic fatty liv…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Liver Disease
• Non-alcoholic Fatty Liver Disease
• Nonalcoholic Steatohepatitis

Drugs mentioned

• Tocotrienol (tocotrienol (vitamin E) supplement)

Snippet

Sponsor: Chandan Sen | Conditions: End Stage Liver Disease, NASH - Nonalcoholic Steatohepatitis | Phase 2 | Status: ACTIVE_NOT_RECRUITING